Breast cancer is frequently classified by receptor status: hormone receptor–positive (HR+), amplified expression of HER2/neu (HER2+), or triple-negative (no hormone receptors, nonamplified HER2) disease (Perou et al., 2000). This evidence concerns the gene ERBB2 and breast carcinoma.